Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original

Determination of binding affinity of tunicamycin with SARS-CoV-2 proteins: Proteinase, protease, nsp2, nsp9, ORF3a, ORF7a, ORF8, ORF9b, envelope and RBD of spike glycoprotein

Ali Adel Dawood*

Microbiology, Dept. of Medical Biology, College of Medicine, University of Mosul. Mosul, Iraq

ABSTRACT

Introduction: Despite the availability of several COVID-19 vaccines, the incidence of infections remains a serious issue. Tunicamycin (TM), an antibiotic, inhibited tumor growth, reduced coronavirus envelope glycoprotein subunit 2 synthesis, and decreased N-linked glycosylation of coronavirus glycoproteins.

Objectives: Our study aimed to determine how tunicamycin interacts with certain coronavirus proteins (proteinase, protease, nsp9, ORF7a, ORF3a, ORF9b, ORF8, envelope protein, nsp2, and RBD of spike glycoprotein). Methods: Several types of chemoo and bioinformatics tools were used to achieve the aim of the study. As a result, virion’s effectiveness may be impaired.

Results: TM can bind to viral proteins with various degrees of affinity. The proteinase had the highest binding affinity with TM. Proteins (ORF9b, ORF8, nsp9, and RBD) were affected by unfavorable donor or acceptor bonds that impact the degree of docking. ORF7a had the weakest affinities.

Conclusions: This antibiotic is likely to effect on SARS-CoV-2 in clinical studies.

© 2022 Elsevier España, S.L.U. All rights reserved.

RESUMEN

Determinación de la afinidad de unión de la tunicamicina con las proteínas del SARS-CoV-2: proteinasa, proteasa, nsp2, nsp9, ORF3a, ORF7a, ORF8, ORF9b, envolvente y RBD de la glicoproteína Spike

Palabras clave: COVID-19, acoplamiento, tunicamicina

* Autor para correspondencia. E-mail address: aad@uomosul.edu.iq.
https://doi.org/10.1016/j.vacun.2022.10.006
1576-9887/© 2022 Elsevier España, S.L.U. All rights reserved.
Objetivos: Nuestro estudio tuvo como objetivo determinar cómo interactúa la tunicamicina con ciertas proteínas del coronavirus (proteínaas, proteasa, nsp9, ORF7a, ORF3a, ORF9b, ORF8, proteína de la envoltura, nsp2 y RBD de glicoproteína de punta).

Métodos: Se utilizaron varios tipos de herramientas de quimioterapia y bioinformática para lograr el objetivo del estudio. Como resultado, la eficacia del virión puede verse afectada.

Resultados: La TM puede unirse a proteínas virales con diversos grados de afinidad. La proteínaas tenía la mayor afinidad de unión con TM. Las proteínas (ORF9b, ORF8, nsp9 y RBD) se vieron afectadas por enlaces donantes o aceptores desfavorables que afectan el grado de acoplamiento. ORF7a tenía las afinidades más débiles.

Conclusiones: Es probable que este antibiótico tenga efecto sobre el SARS-CoV-2 en estudios clínicos.

© 2022 Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

SARS-CoV-2 is the most lethal of the coronaviruses, causing over 4.4 million deaths from coronavirus sickness 2019 (COVID-19) and affecting over 210 million people worldwide through the middle of August 2021. SARS-CoV-2 has a genome that is almost 30 kb long and has 14 open reading frames (ORFs) that encode 27 proteins. It has four structural proteins (surface, envelope, membrane, and nucleocapsid) as well as sixteen non-structural proteins (nsp1-16). Several antiviral medications are now being studied in clinical trials, but reputable clinical trials are becoming increasingly difficult to run as the public’s need for easily available remedies grows. Remdesivir is an antiviral that is now being tested in clinical trials for the treatment of COVID-19. It works by inhibiting RNA synthesis by targeting RdRP. Paxlovid is the first oral antiviral medicine approved by the FDA for adults and children with mild to moderate COVID-19. Paxlovid is a ritonavir-boosted nirmatrelin medication for those aged 12 and above who are at high risk of contracting severe COVID-19, which can lead to hospitalisation or death.

Tunicamycin (TM) is an antibiotic made by S. clavuligerus, S. lysosuperficus, and among other bacteria. TM is a white crystalline powder that is mildly soluble in ethanol, acidic water, chloroform, and benzene, and is soluble in alkaline water and pyridine. There is currently no information available on TM’s pharmacodynamics, absorption, toxicity, or metabolism.

TM causes endoplasmic reticulum stress in cells by blocking the initial step in the production of N-linked glycans in proteins, resulting in a high number of missfolded proteins. The cell cycle is stopped in the G1 phase when the antibiotic prevents glycosylation of N-glycans. Previous research showed that TM might be utilized to treat human colon and prostate cancer cells by inducing apoptosis. TM treatment significantly decreased tumor growth and significantly prolonged the lifetime of tumor-bearing mice in vitro compared to the PBS-treated group. TM has been shown to suppress the production of coronavirus envelope glycoprotein subunit 2 but not the synthesis or glycosylation of envelope glycoprotein subunit 1 during virion generation or release. Infected cells with TGEV in the presence of TM had significantly reduced antigenicity of both surface and membrane proteins. This might support the hypothesis that TM is a glycosylation protein inhibitor. Coronavirus generated spikeless, non-infectious virions that lacked S protein when cultured in the presence of the inhibitor TM. Furthermore, No evidence that TM inhibits N-linked glycans in nonstructural proteins (nsp3, and nsp4) has been found too far.

In vitro, TM has been used to determine the functional importance of N-glycosylation in biological systems, such as cell proliferation and survival, drug sensitivity and resistance.

Fig 1 – A: Chemical structure of tunicamycin. B: crystal structure of TM. C: 3D structure of TM after docking with a protein.
of tumor cells to anti-cancer medicines, and programmed cell death (apoptosis).\textsuperscript{23,24}

TM induces DR5 expression in prostate cancer cells, making it a potent activator of TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. Furthermore, p53 is inactive in PC-3 and DU145 cells. As a result, p53-deficient tumor cells may benefit from a combination of TM and TRAIL treatment. It’s critical to know if TM and TRAIL can be given safely without producing toxicity in normal tissues such as the liver. This data implies that tumor vs normal cell susceptibility to the TM sensitization effect is connected to CHOP’s (C/EBP homologous protein) uneven induction capability. These findings suggest that combining TM with TRAIL to treat hormone-refractory prostate cancer might be beneficial.\textsuperscript{25} On the surface of tumor cells, TM reduced the amount of lectin-binding sites. Not only in parental cells, but also in generated cisplatin-resistant cells, TM enhances in vitro cisplatin sensitivity. In clinical studies, TM has shown to be effective in overcoming cisplatin resistance.\textsuperscript{26} Moreover, TM prevents the production of the MHV E2 glycoprotein but not the synthesis or glycosylation of the transmembrane glycoprotein El, viriogenesis, or viriolysis from cells.\textsuperscript{27}

The goal of our study was to figure out how tunicamycin interacts with specific coronavirus proteins. On the other hand, finding the docking degree of the TM with the protein may be important in determining the likelihood of employing this antibiotic to suppress the virus in clinical trials on mice.

Methods

The reference sequence SARS-CoV-2 (NC 045512.2) was selected as the source of all proteins utilized in this study as follows: Proteinase 3CLpro (PDB: 1P9S), protease (PDB: 1Q2W), nonstructural protein nsp9 (PDB: 1QZ8), ORF7a accessory protein (PDB: 1XAK), ORF3a (PDB: 6XDC), ORF9b (PDB: 7DHG), ORF8 encoded accessory protein (PDB: 7JX6), envelope protein (pentameric transmembrane domain PDB: 7K3G), nonstructural protein nsp2 (PDB: 7MSW), and receptor-binding domain (RBD) of spike glycoprotein (PDB: 6M0J). The structure of tunicamycin was extracted from PubChem.

Prepare protein for docking

After downloading proteins from the Protein Data Bank and loading them into the BIOVIA Discovery Studio Visualizer program, each protein was passed. All water molecules and heteratoms were removed from the total protein after the hierarchical scale was created. To aid molecular fusion, hydrogen polar bonds were introduced.

Molecular docking between Tunicamycin and each viral protein

To determine the interaction of tunicamycin with each protein, we used PyRx software for autodock. The protein structure was converted to macromolecule (pdbqt) type after loading the protein. TM was minimized energy and changed to pdbqt style after loading the legend. VINA wizard was used to conducting molecular docking. After minimizing energy, the entire interaction was carried out. To analyze the structural vision, the top three interactions were chosen.

Determine the molecular docking’s 3D structure

The degree of contact between the protein and the ligand was calculated, and the interaction areas between atoms were carefully mapped. PyMOL software was used to extract the docking’s 3D structure.

Results

According to the findings of this study, tunicamycin can bind to SARS-CoV-2 proteins in a specific region depending on the kind and location of attachment. The PyRx picked 9 fusion models based on the degree of affinity and the quantity of energy based on the docking models for each protein. The top three docking models were chosen based on the highest protein-ligand affinity. Table 1 displays the top three models that can be retrieved after each protein binds tunicamycin.

Proteinase 3CLpro (1P9S)-TM docking

Tunicamycin and proteinase share 5 conventional hydrogen bonding residues (A: ALA-1, A: LEU-3, A: ARG-4, A: LEU-278, and B: ARG-130) and 2 carbon-hydrogen bonding residues (A: TYR-280, and B: ASN-28). There are three possible weakest alky1 interactions (A: LYS-5, B: LYS-5, and B: TYR-280) as illustrated in Fig. 2.

Protease (1Q2W)-TM docking

TM and protease share four typical hydrogen bonding residues (A: ALA-1, A: LEU-3, A: ARG-4, A: LEU-278, and B: ARG-130) and 2 carbon-hydrogen bonding residues (A: TYR-280, and B: ASN-28). There are three possible weakest alky1 interactions (A: LYS-5, B: LYS-5, and B: TYR-280) as illustrated in Fig. 2.

Nonstructural protein nsp9 (1QZ8)-TM docking

TM and nsp9 share four hydrogen bonding residues (A: ASN-95, ASN-96, A: LEU-97, and A: ASN-98) as well as two carbon-hydrogen bonding residues (A: LEU-94, and B: ASN-96). As
Table 1 – Binding affinity and RMSD degree of the top of molecular docking models between viral proteins and TM. The highest binding affinity docking for each protein was selected (blue models).

| Protein-Ligand Docking | Binding Affinity | RMSD/ub | RMSD/lb |
|------------------------|------------------|---------|---------|
| 1P9S_11104835_uff_E=1878.14 | -9.4             | 0       | 0       |
| 1P9S_11104835_uff_E=1878.14 | -9.3             | 8.812   | 4.721   |
| 1P9S_11104835_uff_E=1878.14 | -9.2             | 9.162   | 5.207   |
| 1Q2W_11104835_uff_E=1774.64 | -8.2             | 0       | 0       |
| 1Q2W_11104835_uff_E=1774.64 | -7.9             | 10.756  | 3.817   |
| 1Q2W_11104835_uff_E=1774.64 | -7.9             | 13.31   | 7.184   |
| 1Q2W_11104835_uff_E=1774.64 | -6.4             | 0       | 0       |
| 1Q2W_11104835_uff_E=1774.64 | -6.2             | 25.588  | 20.811  |
| 1Q2W_11104835_uff_E=1774.64 | -6.2             | 22.963  | 19.059  |
| 1XAK_11104835_uff_E=1774.64 | -6.2             | 11.051  | 6.364   |
| 1XAK_11104835_uff_E=1774.64 | -6.9             | 13.824  | 5.495   |
| 1XAK_11104835_uff_E=1774.64 | -8.8             | 0       | 0       |
| 1XAK_11104835_uff_E=1774.64 | -8.5             | 6.972   | 4.478   |
| 1XAK_11104835_uff_E=1774.64 | -8.5             | 6.522   | 3.488   |
| 7DHG_11104835_uff_E=1774.64 | -7.8             | 0       | 0       |
| 7DHG_11104835_uff_E=1774.64 | -7.4             | 31.828  | 26.717  |
| 7DHG_11104835_uff_E=1774.64 | -7.4             | 9.123   | 4.383   |
| 7JX6_11104835_uff_E=1774.64 | -7               | 0       | 0       |
| 7JX6_11104835_uff_E=1774.64 | -7               | 9.401   | 3.118   |
| 7JX6_11104835_uff_E=1774.64 | -6.9             | 11.72   | 4.807   |
| 7K3G_model1_11104835_uff_E=1774.64 | -8         | 0       | 0       |
| 7K3G_model1_11104835_uff_E=1774.64 | -7.9     | 4.09    | 2.628   |
| 7K3G_model1_11104835_uff_E=1774.64 | -7.7     | 2.416   | 1.75    |
| 7MSW_11104835_uff_E=1774.64 | -8.1             | 0       | 0       |
| 7MSW_11104835_uff_E=1774.64 | -7.8             | 28.359  | 24.597  |
| 7MSW_11104835_uff_E=1774.64 | -7.7             | 2.452   | 2.009   |
| RBD_11104835_uff_E=1774.64 | -6.9             | 0       | 0       |
| RBD_11104835_uff_E=1774.64 | -6.8             | 2.528   | 1.817   |
| RBD_11104835_uff_E=1774.64 | -6.8             | 2.109   | 1.058   |

Fig 2 – Molecular docking of 1P9S-TM. A: 2D interaction shows types of fusion in specific residues. B: Crystal structure of proteinase (1P9S) shows the interaction location with TM. C: Molecular docking residues of 1P9S-TM, residues of conventional hydrogen bond (green), residues of carbon-hydrogen bond (cyan), and alkyl residues (magenta).
shown in Fig. 4, there are two probable weakest alkyl interactions (A: PHE-40 and A: VAL-41) as well as two unfavorable acceptor or donor contacts (A: SER-95 and A: LYS-96).

Open reading frame ORF7a accessory protein (1XAK)-TM docking:

Three conventional hydrogen bonding residues (A: PRO-19, A: ASP-54, and A: THR-56), as well as 3 carbon-hydrogen bonding residues (A: HIS-4, A: GLU-13, and A: HIS-50), are shared by TM and ORF7a. As illustrated in Fig. 5, there are two probable weakest alkyl interactions (A: LEU-16, A: LYS-17, and A: CYS-20) as well as a pi-sulfur interaction residue (A: CYS-52).

Open reading frame ORF3a (6XDC)-TM interaction

TM and ORF3a share 5 conventional hydrogen bonding residues (A: ASP-142, A: SER-205, A: TYR-206, B: THR-64, and B: LYS-75) as well as a carbon-hydrogen bonding residue (B: HIS-78). There are six possible weakest alkyl interactions (A: LYS-75, A: HIS-78, A: PHE-79, A: ARG-126, A: ILE-128, and A: LEU-139). As illustrated in Fig. 6, there is additionally one pi-

Fig 3 – Molecular docking of 1Q2W-TM. A: 2D interaction shows types of fusion in specific residues. B: Crystal structure of protease (1Q2W) shows the interaction location with TM. C: Molecular docking residues of 1Q2W-TM, residues of conventional hydrogen bond (green), residues of carbon-hydrogen bond (cyan), alkyl residues (magenta), and unfavorable acceptor bound (red).

Fig 4 – Molecular docking of 1QZ8-TM. A: 2D interaction shows types of fusion in specific residues. B: The crystal structure of nsp9 (1QZ8) shows the interaction location with TM. C: Molecular docking residues of 1QZ8-TM, residues of conventional hydrogen bond (green), residues of carbon-hydrogen bond (cyan), alkyl residues (magenta), pi-donor hydrogen bond (dark cyan), and unfavorable acceptor or donor bond (red).
alkyl bound in the residue (A: TYR-206) and 20 pi-pi-stacked bounds in a single or double.

**ORF9b (7DHG)-TM docking**

TM and ORF9b have three conventional hydrogen bonding residues (B: SER-50, C: SER-259, and C: SER-262) and one carbon-hydrogen bonding residue (C: SER-263) with eight bounds. There are three weakest alkyl interactions (B: PRO-51, C: PHE-256, and C: ARG-431) as well as one pi-alkyl bound. There is unfavorable donor interaction residue (C: ALA-476). All bonds are illustrated in Fig. 7.

**ORF8 encoded accessory protein (7JX6)-TM docking**

TM and ORF8 have three hydrogen bonding residues in common (A: PRO-93, A: ARG-115, and B: ARG-115). Two probable weakest alkyl connections (A: LYS-94 and B: ALA-
51) as well as unfavorable acceptor interaction residue (B: GLU-92). All interactions are illustrated in Fig. 8.

**Envelope protein (7K3G)-TM docking**

One conventional hydrogen bonding residue (A: THR-35) and a carbon-hydrogen bonding residue (B: ALA-32) with 5 boundaries are shared by TM and envelope protein. As shown in Fig. 9, there are seven probable weakest alkyl and pi-alkyl interactions (A: LEU-28, A: ALA-36, B: LEU-28, C: LEU-28, D: VAL-25, D: LEU-28, and E: LEU-28). Although the docking was in the main pocket of the envelope glycoprotein, there was no change in the structure of the protein after binding to TM, Fig. 10.

**Nonstructural protein nsp2 (7MSW)-TM docking**

TM and nsp2 share four hydrogen bonding residues (A: ASN-133, A: LEU-180, A: ASN-183, and A: ASN-328), as well as a carbon-hydrogen bonding residue (A: PRO-181) with seven boundaries. As shown in Fig. 11, there are two probable weakest alkyl and pi-alkyl interactions (A: ILE-104 and A: TYR-124).

**Receptor binding domain (RBD) (6M0J)-TM docking**

TM and RBD of spike glycoprotein share 5 conventional hydrogen bonding residues (E: ARG-346, E: ALA-348, E: TYR-351, E: SER-399, and E: ASN-450). There is a possible weakest alkyl interactions (E: ALA-344, and E: LEU-452) and one
Fig 9 – Molecular docking of 7K3G-TM. A: 2D interaction shows types of fusion in specific residues. B: The crystal structure of envelope protein (7K3G) shows the interaction location with TM. C: Molecular docking residues of 7K3G-TM, residues of conventional hydrogen bond (green), residues of carbon-hydrogen bond (cyan), and alkyl and pi-alkyl residues (magenta).

---

Fig 10 – A: The surface structure of pentameric envelope glycoprotein (7K3G). B: The molecular docking of 7K3G-TM.

---

Fig 11 – Molecular docking of 7MSW-TM. A: 2D interaction shows types of fusion in specific residues. B: Crystal structure of nsp2 (7MSW) shows the interaction location with TM. C: Molecular docking residues of 7MSW-TM, residues of conventional hydrogen bond (green), residues of carbon-hydrogen bond (cyan), and alkyl and pi-alkyl residues (magenta).
Pi-Alkyl bound residue (E: PHE-490). There are unfavorable donor interaction residues (ASN-354) illustrated in Fig. 12. The primary component of the spike glycoprotein through which the virus binds to the Angiotensin-converting enzyme 2 (ACE2) receptor on the host cell is known as RBD. This connection has been established and is identified as ID: 6M0J in the protein data bank. In the current study, we revealed that the tunicamycin binding site in the RBD varies from the ACE2 binding site, which does not effect on the structure of the spike glycoprotein, Fig. 13.

Discussion

Even though a variety of COVID-19 vaccinations are available, the frequency of infections continues to be a major concern. On the other side, the rise in the number of deaths drives scientists to look for a drug that may remove or minimize the number of injuries.

Tunicamycin (TM), a nucleoside antibiotic, is a model for drugs that have significant inhibitory effects on protein maturation. On numerous cases, TM has been employed to determine the nonglycosylated protein component of a viral glycoprotein. TM inhibits subunit 2 of the envelope protein, as well as surface and membrane glycoproteins of coronaviruses, according to a prior study. The glycosylation of coronavirus PTMs like HE and 8ab was decreased by TM. Because TM has been used as an anti-cancer drug and can inhibit coronavirus glycoproteins, we recommend using it to treat SARS-CoV-2. Although TM reduces N-linked glycosylation of coronavirus glycoproteins, there is currently no medication that can inhibit O-linked glycosylation. There have been no clinical investigations of TM’s effect on tissues or viruses, but our findings may pave the path for TM to be used in clinical trials. Tunicamycin and thapsigargin were
shown to decrease cellular stress induced by coronavirus viral and respiratory syncytial virus through distinct pathways for E protein (RSV).\textsuperscript{32} A study revealed that TM decreased extracellular infectious viral production by almost 99%.\textsuperscript{33}

The PyRx program is known to pick seven models of the protein-ligand binding process as having the highest degree of affinity at various locations. The best three out of seven docking models for each protein were chosen as having the highest binding affinity. When the RMSD equals zero, the optimal fusion model for each protein was picked.

The average root-mean-square distance (RMSD) between the best ranking posture of the tested compounds and their binding pose in the individual crystal structures was found to be less than 2 Å, indicating that the program is capable of docking the compounds properly. The ligand may be isolated, and then docking experiments can be performed to verify the docking procedure.\textsuperscript{34} The optimal posture is chosen based on binding energy, ligand-receptor interactions, and active site residues once docking is completed. Simply align both docked poses with the co-crystallized structure and calculate the RMSD; a lower number implies that the docking approach is more accurate. Because the RMSD for the selected models for each protein is large, the greatest affinity was chosen when RMSD/up and RMSD/lp equals zero, as shown in table (1). This is what prompted the algorithm to select the first model with a high affinity for the hydrogen and carbon bonding degree between the molecule and the ligand.\textsuperscript{35,36}

There is a high bonding strength with hydrogen and carbon bonds, as well as the existence of weakly linked alkaline bonds, in the proteinase that had the highest affinity for tunicamycin.\textsuperscript{37,38} The binding of TM to proteinases causes it to be the focus of direct action, altering the enzyme’s activity. Although proteases have a high binding affinity, the antagonist may be affected by the presence of three unfavorable acceptor bonds. Similarly, proteins with unfavorable donor or acceptor bonds that impact the degree of fusion (nsp9, ORF8, ORF8, and RBD of spike glycoprotein) are affected. The ORF7a had the lowest affinity at (-4.9), indicating that TM had no impact on this protein. Similarly, there is a weak binding affinity with TM for (nsp9, ORF8, and RBD).

Binding to TM is a high affinity (-8) for the envelope protein. The pentameric form allows the E protein to dock inside the particular pocket, which is consistent with our earlier research on the binding of doxycycline to the E protein in the same locus where the shape of the protein was altered. Despite the low affinity of the ligation between the TM and the RBD (-6.9), the impact is different because the RBD and ACE2 binding sites are distinct.\textsuperscript{39}

Spike is an essential Coronavirus protein because it connects to the host cell via the ACE2 receptor on the cell membrane’s surface. The ACE2 receptor may be found in nearly all organs, although it is especially prevalent in the epithelial cells of the lungs and small intestine. The virus will be unable to enter the host cell if this protein is missing. There has been a lot of study into finding a mechanism to keep the spike protein from being bound to the ACE2, but most of it has failed, and many of them are still being investigated.\textsuperscript{40,41}

In addition to the poor degree of binding and the existence of undesired donor bonds, the current study discovered that the region of TM binding in the RBD had no effect on the region of protein fusion with the ACE2 receptor. Tunicamycin has been shown to inhibit proteins during their maturation stage, treat cancer cells by blocking the first step in the G1 phase of the cell cycle, inhibit the production of N-linked glycans in proteins, suppress the production of envelope glycoprotein subunit 2, and inhibit the formation of the spike protein. According to the findings of this investigation, tunicamycin can bind to viral proteins with various degrees of affinity. This antibiotic may affect SARS-CoV-2 in clinical studies.

Conclusions

Tunicamycin has been shown to inhibit proteins during their maturation stage, treat cancer cells by blocking the first step in the G1 phase of the cell cycle, inhibit the production of N-linked glycans in proteins, suppress the production of envelope glycoprotein subunit 2, and inhibit the formation of the spike protein. According to the findings of this investigation, tunicamycin can bind to viral proteins with various degrees of affinity. This antibiotic may affect SARS-CoV-2 in clinical studies.

Funding

This work was done with self-supporting.

Author contributions

Designing the idea, choosing programs, writing the manuscript, using software, writing the results, analyze and clarifying the purpose of the study were done by the corresponding author.

Conflict of interest

There is no conflict of interest in this work.

Acknowledgments

The author thanks college of Medicine, University of Mosul for documenting this work.
REFERENCES

1. Angelini MM, Akhhaghour N, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio. 2015;4(4). https://doi.org/10.1128/mBio.00524-13 e00524-13.

2. Woo PC, Lau SK, Lam CW. Discovery of seven novel mammalian and avian coronaviruses in deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and Betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008. https://doi.org/10.1128/jvi.00540-11.

3. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. https://doi.org/10.1016/j.cell.2021.12.032.

4. World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. 2021 Accessed 10 February 2022.

5. Ullrich S, Ekanayake K, Otting G, Nitsche C. Main protease and RNA-dependent RNA polymerase (Nsp12) Mutations on Remdesivir Docking Residues. Med ImmunoRus. 2022;2022. https://doi.org/10.1101/2022.01.26.477782 2001.2026.477782.

6. Unoh Y, et al. Discovery of S-217622, a non-covalent oral protein and RNA-Dependent RNA polymerase (Nsp12) Mutations on Remdesivir Docking Residues. Med ImmunoRus. 2022;24(3):617–28. https://doi.org/10.15789/1563-0625-105-2486.

7. Steenhuyzen J. Could Paxlovid help treat long COVID? Here’s what we know. Global News. 2022 April:https://globalnews.ca/news/8766853/paxlovid-long-covid/.

8. Steenhuysen J. Could Paxlovid help treat long COVID? Here’s what we know. Global News. 2022 April:https://globalnews.ca/news/8766853/paxlovid-long-covid/.

9. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. https://doi.org/10.1016/j.cell.2021.12.032.

10. White TC, Yi Z, Hogue BG. Identification of mouse hepatitis virus virulence. Microb Pathog. 2022;164, 105400.https://doi.org/10.1016/j.micpath.2022.105400.

11. Merlieg JP, Sebbane R. Inhibition of glycosylation with Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand–induced apoptosis in human prostate cancer cells. Cancer Res. 2005;65(14):6364–70.

12. locker JK, Rose JK, Horzinek MC, Rottier PJ. Membrane assembly of the triple-spanning coronavirus M protein. Individually transmembrane domains show preferred orientation. J Biol Chem. 1992;267(20):14094–14098. https://doi.org/10.1016/s0022-2822(03)00235-6.

13. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

14. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

15. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

16. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

17. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

18. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

19. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

20. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

21. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

22. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.

23. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164, 105400. https://doi.org/10.1016/j.micpath.2022.105400.
and apoptosis. PLoS Pathog. 2011;7(10):1–19. https://doi.org/10.1371/journal.ppat.1002315.

33. Rottier P, Horzinek M, Van Der Zeijst B. Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. J Virol. 1981;40(2):350–7 0022-538X/81/1 10350-08 $02.00/0.

34. Holmes KV, Doller EW, Sturman LS. Tunicamycin resistant glycosylation of coronavirus glycoprotein: Demonstration of a novel type of viral glycoprotein. Virology. 1981;115(2):334–44. https://doi.org/10.1016/0042-6822 (81)90115-x.

35. Yamada Y, Liu DX. Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells. J Virol. 2009;83(17):8744–58. https://doi.org/10.1128/jvi.00613-09.

36. Corse E, Machamer CE. Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. J Virol. 2000;74(9):4319–26. https://doi.org/10.1128/jvi.74.9.4319-4326.2000.

37. Tooze SA, Tooze J, Warren GG. Site of addition of N-acetyl-galactosamine to the E1 glycoprotein of mouse hepatitis virus-A59. J Cell Biol. 1988;106(5):1475–87. https://doi.org/10.1083/jcb.106.5.1475.

38. Lavillette D, Barbouché R, Yao Y, Boson B, Cosset FL, Jones IM, et al. Significant redox insensitivity of the SARS-CoV spike glycoprotein: Comparison with HIV envelope. J Biol Chem. 2006;281(14):9200–4. https://doi.org/10.1074/jbc.m512529200.

39. Dawood A, Altobe M. Inhibition of N-linked glycosylation by tunicamycin may contribute to the treatment of SARS-CoV-2. Microbiol Path. 2020;149, 104586. https://doi.org/10.1016/j.micpath.2020.104586.

40. Yamada YK, Yabe M, Ohtsuki T, Taguchi F. Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site. Virus Res. 2000;66(2):149–54. https://doi.org/10.1016/s0168-1702(99)00134-3.

41. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005;65(14):6364–70. https://doi.org/10.1158/0008-5472.can-05-0312.

42. Dawood A, Altobe M, Alrassam Z. Molecular docking of SARS-CoV-2 nucleocapsid protein with angiotensin-converting enzyme II. Mikrobio Zhu. 2021;83(2):82–92. https://doi.org/10.15407/microbioj83.02.082.

43. Dawood A. Mutated COVID-19, May foretells mankind in a great risk in the future. N Mic N Inf. 2020;35. https://doi.org/10.1016/j.nmni.2020.100673.